

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
 and searchable
 NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
 CA/CAPLUS
 NEWS 5 FEB 05 German (DE) application and patent publication number format
 changes
 NEWS 6 MAR 03 MEDLINE and LMEADLINE reloaded
 NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
 NEWS 8 MAR 03 FRANCEPAT now available on STN
 NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
 NEWS 10 MAR 29 WPIFV now available on STN
 NEWS 11 MAR 29 No connect hour charges in WPIFV until May 1, 2004
 NEWS 12 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 13 APR 26 PROMT: New display field available
 NEWS 14 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field
 available
 NEWS 15 APR 26 LITALERT now available on STN
 NEWS 16 APR 27 NLDB: New search and display fields available

 NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:23:46 ON 09 MAY 2004

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'HCAPLUS' ENTERED AT 16:23:54 ON 09 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2004 VOL 140 ISS 20
FILE LAST UPDATED: 7 May 2004 (20040507/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s somatostatin? and modul?

17760 SOMATOSTATIN?

474147 MODUL?

L1 1496 SOMATOSTATIN? AND MODUL?

=> s l1 and diabetes () complicat?

88630 DIABETES

90772 COMPLICAT?

630 DIABETES (W) COMPLICAT?

L2 0 L1 AND DIABETES (W) COMPLICAT?

=> s l1 and diabete? (4w) complication?

88633 DIABETE?

30096 COMPLICATION?

1772 DIABETE? (4W) COMPLICATION?

L3 0 L1 AND DIABETE? (4W) COMPLICATION?

=> s l1 and diabete?

88633 DIABETE?

L4 41 L1 AND DIABETE?

=> s l4 and dt/review

'REVIEW' IS NOT A VALID FIELD CODE

0 DT/REVIEW

L5 0 L4 AND DT/REVIEW

=> s l4 and review/dt

1724217 REVIEW/DT

L6 5 L4 AND REVIEW/DT

=> d l6, ibib abs fhitr, 1-5

L6 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2003:246328 HCAPLUS

DOCUMENT NUMBER: 139:270068

TITLE: Pharmacological agents that directly modulate insulin secretion

AUTHOR(S): Doyle, Maire E.; Egan, Josephine M.

CORPORATE SOURCE: Diabetes Section, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA

SOURCE: Pharmacological Reviews (2003), 55(1), 105-131
CODEN: PAREAQ; ISSN: 0031-6997

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Blood glucose levels are sensed and controlled by the release of hormones from the islets of Langerhans in the pancreas. The β -cell, the insulin-secreting cell in the islet, can detect subtle increases in circulating glucose levels and a cascade of mol. events spanning the initial depolarization of the β -cell membrane culminates in exocytosis and optimal insulin secretion. Here we review these processes in the context of pharmacol. agents that have been shown to directly interact with any stage of insulin secretion. Drugs that **modulate** insulin secretion do so by opening the KATP channels, by interacting with cell-surface receptors, by altering second-messenger responses, by disrupting the β -cell cytoskeletal framework, by influencing the mol. reactions at the stages of transcription and translation of insulin, and/or by perturbing exocytosis of the insulin secretory vesicles. Drugs acting primarily at the KATP channels are the sulfonylureas, the benzoic acid derivs., the imidazolines, and the quinolines, which are channel openers, and finally diazoxide, which closes these channels. Methylxanthines also work at the cell membrane level by antagonizing the purinergic receptors and thus increase insulin secretion. Other drugs have effects at multiple levels, such as the calcineurin inhibitors and **somatostatin**. Some drugs used extensively in research, e.g., colchicine, which is used to study vesicular transport, have no effect at the pharmacol. doses used in clin. practice. We also briefly discuss those drugs that have been shown to disrupt β -cell function in a clin. setting but for which there is scant information on their mechanism of action.

REFERENCE COUNT: 300 THERE ARE 300 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1998:213707 HCAPLUS
 DOCUMENT NUMBER: 128:279034
 TITLE: Hypothalamic and hypophyseal regulation of growth hormone secretion
 AUTHOR(S): Bluett-Pajot, Marie-Therese; Epelbaum, Jacques; Gourdji, Daniele; Hammond, Constance; Kordon, Claude
 CORPORATE SOURCE: Unite de Recherche sur la Dynamique des Systemes Neuroendocriniens (U159), INSERM, Paris, 75014, Fr.
 SOURCE: Cellular and Molecular Neurobiology (1998), 18(1), 101-123
 CODEN: CMNEDI; ISSN: 0272-4340
 PUBLISHER: Plenum Publishing Corp.
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English
 AB A review, with ~150 refs. Regulation of pulsatile secretion of growth hormone (GH) relies on hypothalamic neuronal loops, major transmitters involved in their operation are growth hormone releasing hormone (GHRH) synthesized mostly in arcuate nucleus (ARC) neurons, and **somatostatin** (SRIH), synthesized both in hypothalamus periventricular (PVe) and ARC neurons. Neurons synthesizing both peptides can inhibit each other in a reciprocal manner. Other neuropeptides synthesized in ARC neurons, such as galanin, or in ARC interneurons, such as neuropeptide Y (NPY), are able to **modulate** synthesis and release of GHRH and SRIH into the hypothalamohypophyseal portal system. In addn., the hitherto uncharacterized endogenous ligand of the recently cloned growth hormone releasing peptide receptor, expressed mostly in the ARC, triggers GH

release, presumably by actions on ARC interneurons. Thyroid, gonadal, and adrenal steroid hormones also affect the GHRH-SRIH balance; a differential distribution of sex steroid receptors in the ARC and the Pve is likely to account for the different pattern of GH secretion in male and female animals. Growth hormone itself is able to inhibit the amplitude of GH secretory episodes and to increase their frequency, by entering the brain (presumably by receptor-mediated internalization at the level of the choroid plexus) and acting subsequently on ARC neurons. At the pituitary level, major neurotransmitters regulating GH cells act on receptors of the VIP/PACAP/GHRH family and of the **somatostatin** family, in particular, sst2 and sst3. Those are coupled to accumulation of cAMP as a second messenger. In addn., patch-clamp expts. and measurement of intracellular Ca²⁺ indicate that GH cells present characteristics, GHRH-dependent, but self-maintained Ca²⁺ spikes and [Ca²⁺]_i transients, which reflect adaptive mechanisms to constraints of episodic release. Recent data on transcription factors affecting GH gene expression and somatotrope differentiation are also summarized. Regulation and differentiation of somatotropes also depend upon paracrine processes within the pituitary itself and involve growth factors and several neuropeptides, for instance, vasoactive intestinal peptide, angiotensin 2, endothelin, and activin. Finally, characteristic changes occur in the GH secretory pattern under discrete, pathol. conditions, such as abnormal growth and dwarfism, **diabetes**, and acromegaly, as well as during inflammatory processes.

REFERENCE COUNT: 149 THERE ARE 149 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1998:126168 HCAPLUS
DOCUMENT NUMBER: 128:266280
TITLE: Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
AUTHOR(S): Gromada, J.; Holst, Jens Juul; Rorsman, Patrik
CORPORATE SOURCE: The Symbion Science Park, Novo Nordisk A/S, Department of Islet Cell Physiology, Fruebjergvej 3, Copenhagen, DK-2100, Den.
SOURCE: Pfluegers Archiv (1998), 435(5), 583-594
CODEN: PFLABK; ISSN: 0031-6768
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal; **General Review**
LANGUAGE: English

AB A review with 86 refs. Glucagon-like peptide 1 is a gastrointestinally derived hormone with profound effects on nutrient-induced pancreatic hormone release. GLP-1 **modulates** insulin, glucagon and **somatostatin** secretion by binding to guanine nucleotide binding protein-coupled receptors resulting in the activation of adenylate cyclase and generation of cAMP. In the B-cell, cAMP, via activation of protein kinase A, interacts with a plethora of signal transduction processes including ion channel activity, intracellular Ca²⁺ handling and exocytosis of the insulin-contg. granules. The stimulatory action of GLP-1 on insulin secretion, contrary to that of the currently used hypoglycemic sulfonylureas, is glucose dependent and requires the presence of normal or elevated concns. of the sugar. For this reason, GLP-1 attracts much interest as a possible novel principle for the treatment of human type-2 **diabetes**. Here the authors review the actions of GLP-1 on islet cell function and attempt to integrate current knowledge into a working model for the control of pancreatic hormone secretion.

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1996:93560 HCAPLUS
 DOCUMENT NUMBER: 124:171923
 TITLE: The role of insulin-like growth factors (IGFs) and IGF binding proteins in diabetic nephropathy
 AUTHOR(S): Flyvbjerg, A.; Landau, D.; Kiess, W.; Bondy, C.; Chin, E.; Raz, I.; Phillip, M.; LeRoith, D.
 CORPORATE SOURCE: Institute Experimental Clinical Research, Aarhus, DK-8000, Den.
 SOURCE: International Congress Series (1995), 1100 (Diabetes. 1994), 345-9.
 CODEN: EXMDA4; ISSN: 0531-5131
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English

AB A review with 28 refs. Diabetic kidney disease is characterized by an early increase in kidney size, glomerular vol. and kidney function and later by the development of mesangial proliferation, accumulation of glomerular extracellular matrix and increased urinary albumin excretion (UAE). Insulin-like growth factors (IGFs) have a long and distinguished history in **diabetes** mellitus with possible participation in the development of long-term complications. In exptl. **diabetes**, increased renal size and function is preceded by a rise in the renal IGF-I, IGF binding proteins (IGFBPs), and IGF-II/mannose-6-phosphate receptor (IGF-II/Man-6-P receptor) concn. Diabetic dwarf rats with isolated growth hormone (GH) and IGF-I deficiency exhibit slower and lesser initial renal and glomerular hypertrophy than diabetic controls with intact pituitary, indicating that IGF-I and GH may be involved in the **modulation** of renal enlargement. Strict insulin treatment or administration of a **somatostatin** analog (octreotide) equally inhibits kidney IGF-I accumulation and growth, the latter without affecting blood glucose levels. These results indicate that IGFs act as initiating growth factors for the diabetic renal growth in short-term exptl. **diabetes**. Whether the IGF system is also involved in long-term diabetic renal changes is unknown. However, 6-mo administration of octreotide to diabetic rats reduces diabetic UAE, renal and glomerular hypertrophy without affecting metabolic control. Furthermore, long-term diabetic dwarf rats, with a **diabetes** duration of 6 mo, display a smaller degree of renal and glomerular hypertrophy and rise in UAE, when compared to pituitary intact diabetic rats. Finally, specific changes occur in the renal IGFBP mRNA expression in long-term **diabetes**. In conclusion, the cited studies suggest that a complex IGF system comprising IGF ligands, IGF receptors, and IGFBPs may be involved in the development of the diabetic kidney disease.

L6 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1995:906675 HCAPLUS
 DOCUMENT NUMBER: 123:306680
 TITLE: Intervention in diabetic vascular disease by **modulation** of growth factors
 AUTHOR(S): Serri, Omar; Renier, Genevieve
 CORPORATE SOURCE: Metabolic Unit, Notre-Dame Hospital, Montreal, QC, Can.
 SOURCE: Metabolism, Clinical and Experimental (1995), 44(10,

Suppl. 4), 83-90

CODEN: METAAJ; ISSN: 0026-0495

PUBLISHER:

Saunders

DOCUMENT TYPE:

Journal; **General Review**

LANGUAGE:

English

AB A review, with 106 refs. Several growth factors have been implicated in the derangements of cellular metab. and proliferation that occur in **diabetes**, e.g., kidney mesangial expansion, retinal neovascular formation, and acceleration of atherosclerosis in large vessels. These phenomena contribute to the development and progression of diabetic microvascular and macrovascular disease. Pharmacol. interventions aimed at reducing growth factor alterations, among other actions in diabetic vasculopathy, include a multitude of classes of drugs, such as angiotensin-converting enzyme (ACE) inhibitors, calcium antagonists, lipid-lowering drugs, and **somatostatin** analogs. New potential interventions, ie, antisense oligonucleotide local delivery, are being applied in growth factor research and may prove beneficial in diabetic macrovascular disease.

=>

Table of Contents

☐ Protective Groups in Organic Synthesis

- [Preface to the Third Edition](#)
- [Preface to the Second Edition](#)
- [Preface to the First Edition](#)
- [Contents](#)

☐ Abbreviations

☐ 1— The Role of Protective Groups in Organic Synthesis

☐ 2— Protection for the Hydroxyl Group, Including 1,2- and 1,3-Diols

☐ 3— Protection for Phenols and Catechols

☐ 4— Protection for the Carbonyl Group

☐ 5— Protection for the Carboxyl Group

☐ 6— Protection for the Thiol Group

☐ 7— Protection for the Amino Group

☐ 8— Protection for the Alkyne -CH

☐ 9— Protection for the Phosphate Group

☐ 10— Reactivities, Reagents, and Reactivity Charts


☐ Index

Protective Groups In
Organic Synthesis
Graene Et. al.

5. J. W. Barton, "Protection of N-H Bonds and NR₃," in *Protective Groups in Organic Chemistry*, J. F. W. McOmie, Ed., Plenum Press, New York and London, 1973, pp. 46–56.
6. Y. Wolman, "Protection of the Amino Group," in *The Chemistry of the Amino Group*, S. Patai, Ed., Wiley-Interscience, New York, 1968, Vol. 4, pp. 669–682.
7. E. Gross and J. Meienhofer, Eds., *The Peptides: Analysis: Synthesis, Biology*, Vol. 3: *Protection of Functional Groups in Peptide Synthesis*, Academic Press, New York, 1981.

Formamide:**R₂NCHO (Chart 9)****Formation**

1. 98% HCO₂H, Ac₂O, 25°, 1 h, 78–90% yield.^{1,2} The use of formic acetic anhydride for esterification and amide formation has been reviewed.³
2. HCO₂H, DCC, Pyr, 0°, 4 h, 87–90% yield.⁴ These conditions produce *N*-formyl derivatives of *t*-butyl amino acid esters with a minimum of racemization.
3. HCO₂H, EtN=C=N(CH₂)₃NMe₂·HCl, 0°, 15 min; then *N*-methylmorpholine, 5°, 20 h, 65–96% yield. This method can be used with amine hydrochlorides.⁵
4. C₆F₅OCHO, CHCl₃, rt, 5–30 min, 85–99% yield.⁶

5.  This reagent also formylates alcohols in the presence of added base.⁷

6. *t*-BuMe₂SiCl, DMAP, Et₃N, DMF, 35–60°, 65–85% yield.⁸
7. DMF, silica gel, heat, 5 h, 100% yield,⁹ or DMF, ZrO, heat, 5 h, 92% yield.¹⁰
8. HCO₂Et, heat.¹¹
9. Triethyl orthoformate, 50–100% yield.¹²
10. HCO₂CH₂CN, CH₂Cl₂, rt, 12 h, 62–97% yield.¹³
11. Vinyl formates readily react with amines, alcohols, and phenols to give the formamide or ester.¹⁴

Cleavage

1. HCl, H₂O, dioxane, 25°, 48 h, or reflux, 1 h, 80–95% yield.¹
2. Hydrazine, EtOH, 60°, 4 h, 60–80% yield.¹⁵
3. H₂/Pd-C, THF, HCl, 25°, 5–7 h, quant.¹⁶
4. 15% H₂O₂, H₂O, 60°, 2 h, 80% yield.¹⁷

5. AcCl , PhCH_2OH , 20° , 24 h, or 60° , 3 h, good yields.¹⁸



«Previous»

Page

Go

Next»

Page 496

Phenyl(<i>o</i> -nitrophenyl)methyl	545
2-(2-Nitrophenyl)ethyl	545
6-Nitroveratryl	545
4-Methoxyphenacyl	545
3',5'-Dimethoxybenzoin	546
Urea-Type Derivatives	547
Phenothiazinyl-(10)-carbonyl Derivative	547
<i>N'</i> - <i>p</i> -Toluenesulfonylaminocarbonyl	547
<i>N'</i> -Phenylaminothiocarbonyl	548
Miscellaneous Carbamates	548
<i>t</i> -Amyl	548
<i>S</i> -Benzyl Thiocarbamate	548
Butynyl	548
<i>p</i> -Cyanobenzyl	548
Cyclobutyl	548
Cyclohexyl	548
Cyclopentyl	548
Cyclopropylmethyl	548
<i>p</i> -Decyloxybenzyl	548
Diisopropylmethyl	548

Special -NH Protective Groups

N-Alkyl and N-Aryl Amines

N-Methylamine:




Formation


1. Methylamines are commonly formed by reacting the amine with a methylating agent such as MeI or dimethyl sulfate.
2. Preparation from an amine and TMSCHN_2 (HBF_4 , CH_2Cl_2 , H_2O) has also been explored.
3. For primary aromatic amines: dimethyl carbonate, Y-Zeolite, $130\text{--}150^\circ$, 72–93% yields.¹
4. HCHO , HCO_2H , 5° then reflux, 12 h, 91% yield.^{2,3}

Cleavage

1. The cleavage of a methylamine can be accomplished photochemically in the presence of an electron acceptor such as 9,10-dicyanoanthracene.⁴



2. Photolysis with visible light, DAP^{+2} ; TMSCN . The photochemical reaction generates an iminium ion that is trapped with cyanide.⁵
3. $\text{CH}_2=\text{CHOCOCN}$, K_2CO_3 , CH_2Cl_2 .⁶ The *N*-methyl group of a tertiary amine is converted to a vinyl carbamate that is easily hydrolyzed.
4. I_2 , CaO , THF, MeOH. A dimethylaniline is converted to a monomethylaniline.⁷
5. CS_2 , MeI, THF, 6 h, 30° , 97% yield. *N*-Methylpiperidine is converted to a dithiocarbamate.⁸
- 6.



7. *t*-BuOOH, RuCl₂(Ph₃P)₂, benzene, rt, 3 h, 83% yield. The methyl group is

converted to $t\text{-BuOOCH}_2\text{NR}_2$, which can then be hydrolyzed, releasing the secondary amine.¹⁰ The oxidation of amines has been reviewed.¹¹

8. PhSeH , 160° , 5 days, 68% yield.¹²

9. RuCl_3 , H_2O_2 , MeOH , 55–80% yield.¹³ These conditions convert the methyl to a MOM group that can be removed by hydrolysis.

1. M. Selva, A. Bomben, and P. Tundo, *J. Chem. Soc., Perkin Trans. 1*, 1041 (1997).

2. G. Chelucci, M. Falorni, and G. Giacomelli, *Synthesis*, 1121 (1990).

3. For a review of the Leukart reaction, see M. L. Moore, *Org. React.*, **5**, 301 (1949).

4. J. Santamaria, R. Ouchabane, and J. Rigaudy, *Tetrahedron Lett.*, **30**, 2927 (1989).

5. J. Santamaria, M. T. Kaddachi, and J. Rigaudy, *Tetrahedron Lett.*, **31**, 4735 (1990).

6. J. R. Ferguson, K. W. Lombard, F. Scheinmann, A. V. Stachulski, P. Stjernlöf, and S. Sundell, *Tetrahedron Lett.*, **36**, 8867 (1995); R. A. Olofson, R. C. Schnur, L. Bunes, and J. P. Pepe, *ibid.*, 1567 (1977).

7. K. Acosta, J. W. Cessac, P. N. Rao, and H. K. Kim, *J. Chem. Soc., Chem. Commun.*, 1985 (1994).

8. M. D. Pujol and G. Guillaumet, *Synth. Commun.*, **22**, 1231

9. J. P. Gesson, J. C. Jacquesy, and M. Mondon, *Synlett*, 669 (1990).


10. S.-I. Murahashi, T. Naota, and K. Yonemura, *J. Am. Chem. Soc.*, **110**, 8256 (1988).

11. S.-I. Murahashi, *Angew. Chem., Int. Ed. Engl.*, **34**, 2443 (1995).

12. R. P. Polniaszek and L. W. Dillard, *J. Org. Chem.*, **57**, 4103 (1992).

13. S.-I. Murahashi, T. Naota, N. Miyaguchi, and T. Nakato, *Tetrahedron Lett.*, **33**, 6991 (1992).

***N*-*t*-Butylamine:**



The *t*-butyl group can be cleaved from a cyclopropylamine upon prolonged heating in acid (H_3O^+ , reflux, 3–5 days).¹

1. N. De Kimpe, P. Sulmon, and P. Brunet, *J. Org. Chem.*, **55**, 5777 (1990).

***N*-Allylamine:**




Formation

1. Allyl chloride, $\text{Cu}(0)$, $\text{Cu}(\text{ClO}_4)_2 \cdot 6\text{H}_2\text{O}$, Et_2O , 97% yield.¹

2. AllylOAc, Pd(Ph₃P)₄, diisopropylamine.²
3. Ni(cod)₂, Bu₄N⁺PF₆⁻, dppb, THF, 50°. ³
4. Allyl bromide, K₂CO₃, THF, heat, 75% yield.⁴ This is a fairly general method that has been used widely for the preparation of allylamines.

Cleavage

1. Isomerization to the enamine (*t*-BuOK, DMSO), followed by hydrolysis.⁵
2. Rhodium-catalyzed isomerization.⁶ Ru(cod)(cot) has been used to convert an allylamine into an enamine.⁷





chain nodes :
1 2 3 7 8 9 10 11 12 15 16 17 20 21 22 25 26 27 28 29 30 31 32 33
34 35 36 37 38 44 45 48
chain bonds :
1-2 2-3 3-7 7-8 8-20 10-12 10-11 15-16 16-17 20-21 21-25 21-48 26-44 26-48
27-29 27-28 30-31 31-32 33-34 33-35 36-37 37-38 44-45
exact/norm bonds :
1-2 2-3 3-7 7-8 8-20 10-12 10-11 15-16 16-17 20-21 21-25 26-44 26-48 27-29
27-28 30-31 31-32 33-34 33-35 36-37 37-38 44-45
exact bonds :
21-48

G1:O,S
G2:[*1],[*2],[*3]
G3:[*1],[*2],[*3],[*4]
G4:[*5],[*6],[*7],[*8]

Match level :
1:CLASS 2:CLASS 3:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS 11:CLASS 12:CLASS 15:CLASS
16:CLASS 17:CLASS 20:CLASS 21:CLASS 22:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS 44:CLASS 45:Atom 48:CLASS

C:\stnweb\Queries\4.str



```

chain nodes :
  1 2 3 7 8 9 10 11 12 15 16 17 20 21 22 25 26 27 28 29 34 35 36 38
  39 40
chain bonds :
  1-2 2-3 3-7 7-8 8-20 10-12 10-11 15-16 16-17 20-21 21-25 21-29 26-27 26-29
  27-28 34-35 34-36 38-39 39-40
exact/norm bonds :
  1-2 2-3 3-7 7-8 8-20 10-12 10-11 15-16 16-17 20-21 21-25 26-27 26-29 27-28
  34-35 34-36 38-39 39-40
exact bonds :
  21-29
  
```

G1:O,S

G2:[*1],[*2],[*3]

G3:[*1],[*2],[*3],[*4]



G4:[*5],[*6]

Match level :

```

1:CLASS 2:CLASS 3:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS 11:CLASS 12:CLASS 15:CLASS
16:CLASS 17:CLASS 20:CLASS 21:CLASS 22:CLASS 25:CLASS 26:CLASS 27:CLASS 28:Atom
29:CLASS 34:CLASS 35:CLASS 36:CLASS 38:CLASS 39:CLASS 40:CLASS
  
```


C:\stnweb\Queries\4g.str



chain nodes :

1 2 3 7 8 9 10 11 12 15 16 17 20 21 24 25 26 27 28 29 30 36

chain bonds :

1-2 2-3 3-7 7-8 8-36 10-12 10-11 15-16 16-17 20-27 20-24 20-36 25-26 25-30
27-28 28-29 28-30

exact/norm bonds :

1-2 2-3 3-7 7-8 10-12 10-11 15-16 16-17 20-24 25-26 28-29 28-30

exact bonds :

8-36 20-27 20-36 25-30 27-28

G1:O,S

G2:[*1],[*2],[*3]

G3:[*1],[*2],[*3],[*4]

G4

Match level :

1:CLASS 2:CLASS 3:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS 11:CLASS 12:CLASS 15:CLASS
16:CLASS 17:CLASS 20:CLASS 21:CLASS 24:CLASS 25:CLASS 26:Atom 27:CLASS 28:CLASS
29:CLASS 30:CLASS 36:CLASS